Safety Could Differentiate Nkarta’s CAR-NK Cell Therapy
Allogeneic Therapy Can Be Re-Dosed
Nkarta has updated its early results for its natural killer cell therapy, where it has shown promising efficacy and potentially superior safety to existing CAR-Ts.
You may also be interested in...
Editas Slims Down To Focus On Gene-Editing Sickle Cell Therapy Race
Editas is seen as a slow developer in the CRISPR-based therapeutics field compared with its rivals but its new CEO has unveiled a new strategy to speed progress.
Nkarta Unveils Early But Promising Data For CAR-NK Therapies In AML, NHL
NKX101 in acute myeloid leukemia and NKX019 in non-Hodgkin’s lymphoma showed high complete response rates, but without the toxicity associated with CAR-Ts.
Pfizer Will Struggle To Catch Novo Nordisk With Oral Obesity Treatments
Novo Nordisk reasserted its dominance in the GLP-1 agonist field this week, while Pfizer must hope that one of its two shots on goal is a success.